All In Biotech

Drug Trial Radar · NCT07616375

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

669

Planned (sponsor's estimate)

Start

Sep 28, 2025

Primary completion

Jan 10, 2029

Study completion Apr 3, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, single-arm, open-label, multicenter study to assess the safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.

Conditions

  • Non-cystic Fibrosis Bronchiectasis

Interventions

  • HSK31858, tabletDrug

    HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AETime frame: week 96

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yixing People's Hospital, Yixing, Jiangxi Recruiting

    Yixingcun, Jiangxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.